cyclin-d1 and shogaol
cyclin-d1 has been researched along with shogaol* in 2 studies
Other Studies
2 other study(ies) available for cyclin-d1 and shogaol
Article | Year |
---|---|
6-Shogaol suppresses the growth of breast cancer cells by inducing apoptosis and suppressing autophagy via targeting notch signaling pathway.
Breast cancer is one of the most commonly diagnosed cancer among women globally. Shogaol, the active constituent of many spices belonging to the Zingiberaceae family, has received wide attention among other shogaols in terms of its anticancer activity against different neoplasms. To date, its efficacy at the detailed molecular level against breast cancer has not been established.. In the current study, we investigated the cytotoxic potential and the underlying molecular details of 6-shogaol against breast adenocarcinomacells (MCF-7), and breast ductal carcinoma cells (T47D). Cytotoxicity assay, cell cycle analysis. Real-time PCR (qPCR), apoptosis and autophagy techniques were used for the determination and molecular investigation of its anticancer properties.. 6-Shogaol is a promising candidate to be considered as a treatment of breast cancer. Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Breast Neoplasms; Catechols; Cell Proliferation; Cisplatin; Cyclin D1; Dose-Response Relationship, Drug; Female; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Oxaliplatin; Receptors, Notch; Signal Transduction; Transcription Factor HES-1 | 2020 |
Targeting cancer stem cells in breast cancer: potential anticancer properties of 6-shogaol and pterostilbene.
Breast cancer stem cells (BCSCs) constitute a small fraction of the primary tumor that can self-renew and become a drug-resistant cell population, thus limiting the treatment effects of chemotherapeutic drugs. The present study evaluated the cytotoxic effects of five phytochemicals including 6-gingerol (6-G), 6-shogaol (6-S), 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone (5-HF), nobiletin (NOL), and pterostilbene (PTE) on MCF-7 breast cancer cells and BCSCs. The results showed that 6-G, 6-S, and PTE selectively killed BCSCs and had high sensitivity for BCSCs isolated from MCF-7 cells that expressed the surface antigen CD44(+)/CD24(-). 6-S and PTE induced cell necrosis phenomena such as membrane injury and bleb formation in BCSCs and inhibited mammosphere formation. In addition, 6-S and PTE increased the sensitivity of isolated BCSCs to chemotherapeutic drugs and significantly increased the anticancer activity of paclitaxel. Analysis of the underlying mechanism showed that 6-S and PTE decreased the expression of the surface antigen CD44 on BCSCs and promoted β-catenin phosphorylation through the inhibition of hedgehog/Akt/GSK3β signaling, thus decreasing the protein expression of downstream c-Myc and cyclin D1 and reducing BCSC stemness. Topics: Antineoplastic Agents; Breast Neoplasms; Catechols; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Female; Humans; Neoplastic Stem Cells; Oncogene Protein p55(v-myc); Signal Transduction; Stilbenes | 2015 |